What Happened?
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations, and sales were underwhelming, coming in line with expectations. We struggled to find many positives in these results, especially because EPS missed. Overall, this quarter could have been better.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy United Therapeutics? Access our full analysis report here, it’s free.
What The Market Is Telling Us
United Therapeutics’s shares are not very volatile and have only had 7 moves greater than 5% over the last year. Moves this big are rare for United Therapeutics and indicate this news significantly impacted the market’s perception of the business.
United Therapeutics is down 12.1% since the beginning of the year, and at $316.48 per share, it is trading 22.8% below its 52-week high of $410 from November 2024. Investors who bought $1,000 worth of United Therapeutics’s shares 5 years ago would now be looking at an investment worth $2,991.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
